Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
Madappa N. Kundranda, Antonio Cubillo Gracián, Syed F. Zafar, E. Meiri, Johanna C. Bendell, Hana Algül, Fernando Rivera, Eugene R. Ahn, David Watkins, Uwe Pelzer, Veena Charu, Alena Zalutskaya, Geoffrey Kuesters, J. Marc Pipas, Sergio Santillana, Vasileios Askoxylakis, Andrew H. Ko
Topics & Concepts
GemcitabineMedicineNab-paclitaxelPaclitaxelPancreatic cancerOncologyDeoxycytidinePlaceboInternal medicineChemotherapyCancerPathologyAlternative medicineGrowth Hormone and Insulin-like Growth FactorsPancreatic and Hepatic Oncology ResearchHER2/EGFR in Cancer Research